Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05413850 · ClinicalTrials.gov registry record · Phase 1
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
A Phase 1 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, sponsored by Blue Earth Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 19
- Study locations
NCT05413850 is a Phase 1 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Blue Earth Therapeutics. The registered enrollment target is 82 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 19 study locations across 6 states.
The verdict
NCT05413850, a Phase 1 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Blue Earth Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 19
- Study locations
Study Summary
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Conditions Studied
Interventions
- DRUG Lutetium (177Lu) rhPSMA-10.1 Injection
- DIAGNOSTIC_TEST 18F-rhPSMA-7.3 injection (in phase 1 only)
Study Locations (19)
Other
- Jules Bordet Institute - Brussels
- Saint Luc University Hospital - Brussels
- University Hospital Ghent - Ghent
- University Hospital Leuven - Leuven
- University Hospital Center Sart-Tilman - Liège
- University Hospital Essen - Essen
- Hospital Rechts der Isar - Munich
- Meander Medisch Centrum - Amersfoort
- Bristol Hematology and Oncology Center - Bristol
- Beatson West of Scotland Cancer Center - Glasgow
- St Bartholomew's Hospital - London
- James Cook University Hospital - Middlesbrough
- Weston Park - Sheffield
- University Hospital Southampton NHS Foundation Trust - Southampton
Florida
- Biogenix Molecular LLC - Miami
Georgia
- Emory University Hospital - Atlanta
Nebraska
- XCancer Omaha / Urology Cancer Center - Omaha
New York
- Weill Cornell Medicine - New York - Presbyterian Hospital - New York
Gelderland
- Radboud UMC - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05413850
The ClinicalTrials.gov registry entry for NCT05413850 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Blue Earth Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lutetium (177Lu) rhPSMA-10.1 Injection is the first listed.
NCT05413850 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05413850 about?
NCT05413850 is a clinical study titled "Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection". To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
What is the current status of trial NCT05413850?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2022-07-20. Estimated completion is 2028-03-31.
What conditions does trial NCT05413850 study?
This clinical trial studies the following conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Diseases.
What interventions are being tested in trial NCT05413850?
The interventions under investigation include: Lutetium (177Lu) rhPSMA-10.1 Injection (DRUG), 18F-rhPSMA-7.3 injection (in phase 1 only) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05413850?
This trial is sponsored by Blue Earth Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05413850 being conducted?
This trial has 19 study locations across Florida, Georgia, Nebraska, New York, Gelderland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Prostate Cancer
All registered trials for this condition
Metastatic Castration-Resistant Prostate Cancer
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.